• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

by Sarah Moniz | Aug 15, 2018

Development of Scoring Functions for Antibody Sequence Assessment and Optimization

Development of Scoring Functions for Antibody Sequence Assessment and Optimization

by Adam | Oct 22, 2016

Development of Scoring Functions for Antibody Sequence Assessment and Optimization. Boehringer Ingelheim Pharma PLoS One. 2013; 8(10) [Use of ISPRI tool to develop Humanized antibody concept].
Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company

Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company

by Adam | Oct 22, 2016

Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf
Computational vaccinology and the ICoVax 2012 workshop

Computational vaccinology and the ICoVax 2012 workshop

by Adam | Oct 22, 2016

BMC Bioinformatics. 2013;14 Suppl 4:I1.doi: 10.1186/1471-2105-14-S4-I1. Epub 2013 Mar 8. PubMed PMID: 23514034; PubMed Central PMCID: PMC3599086.
Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011

Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011

by Adam | Oct 22, 2016

Human Vaccines & Immunotherapeutics 2013; 9:1598 – 1607; PMID: 23846304; https://dx.doi.org/10.4161/hv.25598
« Older Entries

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline